Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.42 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6985885 | 0.84 | HRH3 (0.56) | HRH3KCNH2ATR | |
| SCHEMBL6989539 | 0.78 | SCD5 (0.55) | FABP4HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL3703633 | 0.77 | RAB9A (0.48) | FABP4 | |
| SCHEMBL6986701 | 0.77 | FABP4 (0.41) | HRH3FABP4HCRTR2HCRTR1OPRK1 | |
| SCHEMBL3703636 | 0.77 | RAB9A (0.48) | FABP4 | |
| SCHEMBL6985880 | 0.77 | FABP4 (0.41) | HRH3FABP4HCRTR2HCRTR1OPRM1 | |
| SCHEMBL6988095 | 0.77 | FABP4 (0.41) | HRH3FABP4HCRTR2HCRTR1AKR1C3 | |
| SCHEMBL6992252 | 0.77 | FABP4 (0.43) | FABP4HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL18425650 | 0.76 | HRH3 (0.40) | HRH3KCNH2HCRTR2 | |
| SCHEMBL18425649 | 0.76 | HRH3 (0.40) | HRH3KCNH2HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889683-B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | MERCK SHARP & DOHME CORP. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | MERCK SHARP & DOHME LLC | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | HRH3 2878/4885FABP4 1/4885KCNH2 4810/4885 |
| US-20120122837-A1 | INHIBITORS OF FATTY ACID BINDING PROTEIN | FABP4, FABP1, FABP3 | HRH3 4807/4885FABP4 1/4885KCNH2 4745/4885 |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | HRH3 2878/4885FABP4 1/4885KCNH2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.